These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 15480571

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical effects of strontium ranelate in women with postmenopausal osteoporosis.
    Delmas PD.
    Osteoporos Int; 2005 Jan; 16 Suppl 1():S16-9. PubMed ID: 15578158
    [Abstract] [Full Text] [Related]

  • 3. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
    Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY.
    N Engl J Med; 2004 Jan 29; 350(5):459-68. PubMed ID: 14749454
    [Abstract] [Full Text] [Related]

  • 4. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
    O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY.
    Cochrane Database Syst Rev; 2006 Jul 19; (3):CD005326. PubMed ID: 16856092
    [Abstract] [Full Text] [Related]

  • 5. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
    Seeman E.
    Curr Opin Rheumatol; 2006 Jun 19; 18 Suppl 1():S17-20. PubMed ID: 16735841
    [Abstract] [Full Text] [Related]

  • 6. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
    Meunier PJ, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P, Cormier C, Isaia G, Badurski J, Wark JD, Collette J, Reginster JY.
    Osteoporos Int; 2009 Oct 19; 20(10):1663-73. PubMed ID: 19153678
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
    Adami S.
    Bone; 2006 Feb 19; 38(2 Suppl 1):23-7. PubMed ID: 16434247
    [Abstract] [Full Text] [Related]

  • 9. Strontium ranelate: an increased bone quality leading to vertebral antifracture efficacy at all stages.
    Ortolani S, Vai S.
    Bone; 2006 Feb 19; 38(2 Suppl 1):19-22. PubMed ID: 16455319
    [Abstract] [Full Text] [Related]

  • 10. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age.
    Seeman E, Boonen S, Borgström F, Vellas B, Aquino JP, Semler J, Benhamou CL, Kaufman JM, Reginster JY.
    Bone; 2010 Apr 19; 46(4):1038-42. PubMed ID: 20026265
    [Abstract] [Full Text] [Related]

  • 11. Strontium ranelate: a new paradigm in the treatment of osteoporosis.
    Reginster JY, Deroisy R, Jupsin I.
    Drugs Today (Barc); 2003 Feb 19; 39(2):89-101. PubMed ID: 12698204
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
    O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY.
    Cochrane Database Syst Rev; 2006 Oct 18; 2006(4):CD005326. PubMed ID: 17054253
    [Abstract] [Full Text] [Related]

  • 14. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.
    Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ.
    J Clin Endocrinol Metab; 2005 May 18; 90(5):2816-22. PubMed ID: 15728210
    [Abstract] [Full Text] [Related]

  • 15. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis.
    Roux C, Fechtenbaum J, Kolta S, Isaia G, Andia JB, Devogelaer JP.
    Ann Rheum Dis; 2008 Dec 18; 67(12):1736-8. PubMed ID: 18713788
    [Abstract] [Full Text] [Related]

  • 16. Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover.
    Collette J, Bruyère O, Kaufman JM, Lorenc R, Felsenberg D, Spector TD, Diaz-Curiel M, Boonen S, Reginster JY.
    Osteoporos Int; 2010 Feb 18; 21(2):233-41. PubMed ID: 19436941
    [Abstract] [Full Text] [Related]

  • 17. Strontium ranelate: short- and long-term benefits for post-menopausal women with osteoporosis.
    Roux C.
    Rheumatology (Oxford); 2008 Jul 18; 47 Suppl 4(Suppl 4):iv20-22. PubMed ID: 18556647
    [Abstract] [Full Text] [Related]

  • 18. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia.
    Seeman E, Devogelaer JP, Lorenc R, Spector T, Brixen K, Balogh A, Stucki G, Reginster JY.
    J Bone Miner Res; 2008 Mar 18; 23(3):433-8. PubMed ID: 17997711
    [Abstract] [Full Text] [Related]

  • 19. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ.
    Arthritis Rheum; 2008 Jun 18; 58(6):1687-95. PubMed ID: 18512789
    [Abstract] [Full Text] [Related]

  • 20. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).
    Kanis JA, Johansson H, Oden A, McCloskey EV.
    Osteoporos Int; 2011 Aug 18; 22(8):2347-55. PubMed ID: 21287148
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.